Forte Biosciences, INC 8-K filings

Global immunology company argenx will acquire Forte Biosciences for $77 per share in cash, adding Forte's lead drug candidate FB102 to its pipeline.

Forte Biosciences announced positive top-line results from its Phase 1b study of FB102 in vitiligo, showing statistically significant improvements in facial skin depigmentation.

Forte Biosciences held its 2026 annual meeting, where stockholders approved an amended equity incentive plan and ratified the appointment of KPMG LLP.

Forte Biosciences announced its first quarter 2026 financial results, reporting increased R&D expenses and a net loss, while also highlighting the FDA's Fast Track Designation for its FB102 therapeutic candidate in celiac disease.

Forte Biosciences announced the pricing of a $150 million public offering of common stock, with net proceeds expected to fund clinical development and general corporate purposes.

Forte Biosciences announced its full year 2025 financial results and provided updates on the clinical development of its lead therapeutic candidate, FB102, for autoimmune diseases.

Forte Biosciences announced its third quarter 2025 financial results and provided an update on its FB102 clinical programs, with three key trial readouts anticipated in 2026.

Forte Biosciences announced its second quarter 2025 financial results and provided updates on its FB102 clinical programs, with three key trial readouts expected in 2026.

Forte Biosciences, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock and pre-funded warrants, expecting to raise approximately $75 million in gross proceeds to fund its clinical and preclinical development into 2027.

Forte Biosciences announced positive Phase 1b clinical trial data for its lead program FB102 in celiac disease, paving the way for a Phase 2 study initiation.

Forte Biosciences, Inc. announced the successful election of three Class II directors and the ratification of KPMG LLP as its independent registered public accounting firm at its 2025 annual meeting of stockholders.

Forte Biosciences reports its Q1 2025 financial results, highlighting increased R&D spending and progress in its FB102 clinical trials for celiac disease and vitiligo.

Forte Biosciences has scheduled its annual meeting for May 29, 2025, and announced revised deadlines for stockholders to submit proposals and director nominations.

Forte Biosciences reports its full year 2024 results, highlighting progress in the development of FB102, including the completion of a healthy volunteer study and the initiation of a celiac patient trial.

Forte Biosciences' stockholders have approved an amended and restated 2021 Equity Incentive Plan to attract and retain key personnel.

Forte Biosciences presented updates on its FB102 development program, targeting various autoimmune diseases, at its R&D Day on December 3, 2024.

Forte Biosciences has successfully raised $53 million through a private placement to fund the clinical development of its autoimmune drug candidate, FB102.

Forte Biosciences reported its third quarter 2024 financial results and provided an update on the clinical development of its lead drug candidate, FB102, including the start of a celiac disease trial.

Forte Biosciences has appointed two new independent directors, resolved a legal dispute, and established a strategic committee following the resignation of two board members.

Forte Biosciences has executed a 1-for-25 reverse stock split, effective August 28, 2024, to consolidate its shares and adjust its stock price.

Forte Biosciences' stockholders approved an amended equity incentive plan and a reverse stock split at its annual meeting on August 20, 2024.

Forte Biosciences reported its second quarter 2024 financial results and provided an update on the progress of its FB102 clinical program, including the initiation of a celiac disease patient study.

Forte Biosciences has reached a settlement with Camac Fund, resolving a legal dispute and leading to board changes and a strategic review.

Forte Biosciences announced its first quarter 2024 financial results and provided an update on the progress of its lead drug candidate, FB102.

Forte Biosciences announced progress in its clinical-stage development of FB-102, a novel therapy for autoimmune diseases, alongside its year-end financial results.

Forte Biosciences has amended its 8-K filing to disclose that it will hold an advisory vote on executive compensation every three years, following a shareholder vote at its annual meeting.